Asserter profile

HAEMONETICS CORPORATION

operating company8 patents now8 ever6 cases filed during tenure2 connections

Also seen as: Haemonetics Corporation

PTAB exposure

8of this entity’s patents have been challenged at PTAB (8 total proceedings).

Two-hop network

Edges marked ⚖️ overlap with at least one infringement suit filed during the receiving entity’s tenure with the patent. Bold-bordered = this entity. Red = NPE; orange = shell LLC; green = defensive aggregator; blue = operating company.

flowchart LR
    Nhaemonetics["HAEMONETICS CORPORATION"]
    Nragusa_michael["RAGUSA, MICHAEL"]
    Nmichael_ragusa["Michael Ragusa"]
    Nragusa_michael ==>|"⚖️ 2020 · Assignment · 10980926"| Nhaemonetics
    Nragusa_michael ==>|"⚖️ 2021 · Assignment of Assignor's Interest · 12186474"| Nhaemonetics
    Nmichael_ragusa -->|"2021 · Assignment · 12171916"| Nhaemonetics
    Nmichael_ragusa ==>|"⚖️ 2025 · Corrective Assignment · 12171916"| Nhaemonetics
    Nmichael_ragusa -->|"2022 · Assignment · 11738124"| Nhaemonetics
    Nmichael_ragusa ==>|"⚖️ 2025 · Corrective Assignment · 11738124"| Nhaemonetics
    Nmichael_ragusa ==>|"⚖️ 2018 · Assignment of Assignor's Interest · 10792416"| Nhaemonetics
    Nragusa_michael ==>|"⚖️ 2018 · Assignment of Assignor's Interest · 10758652"| Nhaemonetics
    Nragusa_michael ==>|"⚖️ 2025 · Assignment · 12377204"| Nhaemonetics
    Nragusa_michael ==>|"⚖️ 2020 · Assignment of Assignor's Interest · 10980934"| Nhaemonetics
    classDef focal fill:#fef3c7,stroke:#92400e,stroke-width:3px,color:#1c1917
    classDef npe fill:#fee2e2,stroke:#be123c,stroke-width:2px,color:#1c1917
    classDef shell fill:#fed7aa,stroke:#9a3412,stroke-width:2px,color:#1c1917
    classDef defensive fill:#dcfce7,stroke:#15803d,stroke-width:2px,color:#1c1917
    classDef operating fill:#e0f2fe,stroke:#075985,stroke-width:1px,color:#1c1917
    class Nhaemonetics focal

Patents currently held (8)

Connected entities (2)

Correspondent attorneys (5)

Attorneys / firms recorded with USPTO when this entity received a patent. Recurrence is the signal — many firms do both NPE and operating-company patent work, so a single appearance doesn’t mean much.